Higher Priced Older Pharmaceuticals: How Should We Respond?. (Record no. 2761)

MARC details
000 -LEADER
fixed length control field 02636nam a22003017a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 171017s20172017 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0012-3692
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 29017958
245 ## - TITLE STATEMENT
Title Higher Priced Older Pharmaceuticals: How Should We Respond?.
251 ## - Source
Source Chest. , 2017 Oct 07
252 ## - Abbreviated Source
Abbreviated source Chest. , 2017 Oct 07
253 ## - Journal Name
Journal name Chest
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2017
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2018
266 ## - Date added to catalog
Date added to catalog 2017-10-17
501 ## - WITH NOTE
Local holdings Available online from MWHC library: 1935 - present, Available in print through MWHC library: 1999 - 2006
520 ## - SUMMARY, ETC.
Abstract We and our patients have been aware of the high cost of medications in the United States for decades. However, we are recently witnessing a relatively new phenomenon: exponential price increases for some older pharmaceuticals that have been available for years. To assist practitioners in how to respond to the issue of higher priced pharmaceuticals, an interprofessional session was developed and held at CHEST 2016 in Los Angeles. The session proceedings and a few updates are presented here to summarize what pulmonologists, a sarcoidosis expert, a retired executive of a medical society, pharmaceutical company, pharmacy, and an ethicist advise that we do about the problem. Because the comments presented at the session and in this manuscript represent the opinions of each of the authors, this commentary in essence is an compilation of 9 editorials. It does not represent a comprehensive discussion of the field of pricing of drugs. In reflecting upon the answers to the questions posed, and regardless of their sector of healthcare, all participants stated that they focused on the patient. However, actually providing patient-focused care (i.e., the care defined from the patient's perspective) is another matter. In order to significantly improve patient satisfaction and health care outcomes, patient-focused care needs to embody the 3 Cs of 1) communication, 2) continuity of care, and 3) concordance of expectations (i.e., finding the common ground). Therefore, we discuss how the 3 Cs apply to responses to higher priced pharmaceuticals. Copyright (c) 2017. Published by Elsevier Inc.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element PubMed-not-MEDLINE -- Not indexed
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Department Ethics
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors McGrath, Norine A
790 ## - Authors
All authors Baughman RP, Irwin RS, Manaker S, McGrath NA, Metersky ML, Otulana T, Sussman AJ, Weinberger SE
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1016/j.chest.2017.09.042">https://dx.doi.org/10.1016/j.chest.2017.09.042</a>
Public note https://dx.doi.org/10.1016/j.chest.2017.09.042
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 10/17/2017   29017958 29017958 10/17/2017 10/17/2017 Journal Article

Powered by Koha